Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Effexor XR Follow-On Desvenlafaxine NDA Submitted

This article was originally published in The Pink Sheet Daily

Executive Summary

Assuming a standard FDA review, desvenlafaxine could be brought to market more than three years before Effexor XR faces generic competition.
Advertisement

Related Content

Wyeth’s Desvenlafaxine Advisory Committee Is Cancelled
Wyeth’s Desvenlafaxine Advisory Committee Is Cancelled
Teva’s Effexor Generic Launches Following ANDA Approval
Teva’s Effexor Generic Launches Following ANDA Approval
Wyeth Plans To Launch Lybrel, DVS-233 In 2007 After Resolving Manufacturing Issues
Wyeth Plans To Launch Lybrel, DVS-233 In 2007 After Resolving Manufacturing Issues
Effexor XR To Go Generic In 2010 Under Settlement Between Teva and Wyeth
Effexor XR To Go Generic In 2010 Under Settlement Between Teva and Wyeth
Wyeth Sales Growth Not Dependent On Effexor XR, CEO Essner Says

Topics

Advertisement
UsernamePublicRestriction

Register

PS061446

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel